Secondary outcomes
Graves’ disease
ADVERSE EFFECTS
Throughout the follow-up period, there were significant differences in the concentrations of FT3, FT4, TSH, and TRAb between the AZA1, AZA2, and control groups. However, there were no significant differences in TV between the groups. At the end of the follow-up, there were no significant differences in the concentrations of FT3, FT4, and TSH between the AZA1 and AZA2 groups. However, the concentration of TRAb was significantly lower in the AZA1 group compared with the AZA2 group. Changes in thyroid parameters in the three studied groups along 1 year.We found that after 3 months of therapy, the decrease in FT4 concentration was significantly faster in the AZA2 group compared with the AZA1 group, with a mean difference of 3.56 ng/dl versus 2.67 ng/dl, respectively (At the end of the 12-month follow-up period, the relapse rate was slightly higher in the control group compared with either the AZA1 or AZA2 group, but the difference was not statistically significant (10.0%, 4.4%, 4.4%, Adverse effects of the medications used in the study.Adding AZA to conventional therapy resulted in a significant decrease in the average cost of Graves’ disease treatment compared with conventional therapy alone. This decrease was due to a lower frequency of specialist consultations, lower costs of definitive treatment (such as thyroidectomy and RAI), and fewer absenteeism days (A tornado diagram of different costs on exposure to Azhatioprine and conventional therapy versus conventional therapy only for three years of follow up. EGP, Egyptian pound.